

August 2, 2023

To,  
Online Surveillance Team,  
BSE Limited,  
P J Towers,  
Dalal Street,  
Mumbai -400001

Dear Sir/Madam

**Sub: Clarification/ Confirmation on news item appearing in "moneycontrol.com"**

This has reference to your above email seeking clarification on the subject matter.

In this regard, please note that the news report is speculative in nature and as a matter of policy, the Company does not comment on speculative matters.

The Company has been disclosing the material information in accordance with applicable law, including Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**"), its policy on determination of materiality for disclosures and its policy on the code of practices and procedures for fair disclosure of unpublished price sensitive information. The Company is aware and shall comply with its obligations under the applicable regulations and policies.

We hereby clarify that there is no information currently with the Company that is reportable to the stock exchanges pursuant to the Listing Regulations and relevant policies.

Request you to kindly take the same on record.

Yours faithfully,  
**For Glenmark Life Sciences Limited**

**Rudalf Corriea**  
**Company Secretary & Compliance Officer**